AI assistant
Q32 Bio Inc. — Director's Dealing 2020
Mar 18, 2020
34891_dirs_2020-03-18_f2a9b8b5-c1a7-43df-bed0-dc8ab1423708.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2020-03-17
Reporting Person: Kelly Timothy P (See Remarks)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-03-17 | Common Stock | S | 1315 | $13.0103 | Disposed | 0 | Direct |
Footnotes
F1: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2018.
F2: Consists of 1,315 shares acquired under the Issuer's Employee Stock Purchase Plan on February 28, 2020.
F3: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $12.60 to $13.48. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.